Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 09 tags : Therapeutics save search
Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium
Published: 2021-12-09 (Crawled : 00:00) - globenewswire.com
CNTX | $1.48 8.82% 23K
|
Health Technology
|
| O: 18.21%
H: 3.38%
C: -27.3%
therapeutics symposium positive cancer breast cancer ona-xr
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics
Published: 2021-12-09 (Crawled : 23:00) - prnewswire.com
SWKH | $17.2 -0.29% 4.2K
|
Miscellaneous
|
| O: 0.63%
H: 0.26%
C: -0.16%
CARA | $0.7242 -0.85% 49K
|
Health Technology
|
| O: 1.21%
H: 1.12%
C: -3.35%
biopharma therapeutics milestone
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial
Published: 2021-12-09 (Crawled : 22:00) - biospace.com/
SRNE | $0.015 140K
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics opioid positive results phase 3 topline
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
Published: 2021-12-09 (Crawled : 20:00) - biospace.com/
APRE | $5.1201 790
|
Health Technology
|
| O: 13.62%
H: 0.4%
C: -10.07%
clinical hold fda therapeutics
Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) CongressSuber Huang, MD, MBA, FASRS will present data from the Phase 3 pivotal NORSE TWO registration trial
Published: 2021-12-09 (Crawled : 20:00) - biospace.com/
OTLK | News P | $8.25 1.98% 54K
|
Health Technology
|
| O: 6.0%
H: 1.57%
C: -6.29%
trial therapeutics retina phase 3
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
SRNE | $0.015 140K
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics potential opioid positive therapy results phase 3 topline
Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF®
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
HRTX M | $3.125 20.66% 2.5M
|
Health Technology
|
| O: 0.72%
H: 18.55%
C: 10.58%
zynrelef fda expansion fda approval approval therapeutics
Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
CYTH | $1.26 6.8K
|
Professional, Scientific, and T...
|
| O: -1.49%
H: 3.9%
C: -2.6%
trappsol treatment ema ongoing therapeutics disease
Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
ALGS | $0.859 7.24% 57K
|
Health Technology
|
| O: -1.88%
H: 4.8%
C: -7.43%
alg-0550 health drug therapeutics phase 1 nash
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
Published: 2021-12-09 (Crawled : 14:00) - biospace.com/
ATRA | $0.7073 1.42% 180K
|
Health Technology
|
| O: -2.59%
H: 1.04%
C: -5.89%
ata2271 solid tumors therapeutics therapy results iot t-cell
Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms
Published: 2021-12-09 (Crawled : 14:00) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 10.22%
H: 1.36%
C: -2.71%
acer-801 treatment clearance therapeutics
Anavo Therapeutics Announces the Appointment of Charles McDermott as Chairman of the Board
Published: 2021-12-09 (Crawled : 13:30) - biospace.com/
KALA | $6.33 4.1K
|
Health Technology
|
| O: 1.18%
H: 1.45%
C: -4.65%
therapeutics
Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress
Published: 2021-12-09 (Crawled : 13:30) - globenewswire.com
OTLK | News P | $8.25 1.98% 54K
|
Health Technology
|
| O: 6.0%
H: 1.57%
C: -6.29%
therapeutics retina
Vivos Therapeutics Announces Registration with Health Canada to Manufacture and Sell Sleep Disorder, Snoring and Sleep Apnea Appliances to Canadian Dentists
Published: 2021-12-09 (Crawled : 13:00) - globenewswire.com
VVOS | $2.64 18K
|
Health Technology
|
| O: 10.15%
H: 4.44%
C: -2.39%
health order therapeutics
Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease
Published: 2021-12-09 (Crawled : 13:00) - biospace.com/
FMTX | $20.01 -0.15%
|
Health Technology
|
| O: -7.87%
H: 4.0%
C: -0.34%
therapeutics disease granted
Entrada Therapeutics Reports Third Quarter 2021 Financial Results
Published: 2021-12-09 (Crawled : 12:30) - globenewswire.com
TRDA | $13.22 0.92% 21K
|
Professional, Scientific, and T...
|
| O: -3.98%
H: 4.57%
C: -0.94%
financial results therapeutics results
Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors
Published: 2021-12-09 (Crawled : 12:30) - biospace.com/
GSK | News | $40.995 1.0% 590K
|
Health Technology
|
| O: 0.68%
H: 0.08%
C: -0.23%
A | $139.1 3.88% 790K
|
Health Technology
|
| O: 1.16%
H: 0.96%
C: -1.21%
MRKR | $4.46 6.44% 5.8K
|
Consumer Services
|
| O: 8.11%
H: 2.5%
C: -3.33%
therapeutics biotech iot
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
Published: 2021-12-09 (Crawled : 12:30) - globenewswire.com
ACHL | $0.8199 3.79% 30K
|
Manufacturing
|
| O: 5.43%
H: 6.09%
C: -5.15%
therapeutics positive t-cell
Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - Dec 09, 2021
Published: 2021-12-09 (Crawled : 08:00) - biospace.com/
RLMD | $3.91 1.03% 56K
|
Health Technology
|
| O: -3.85%
H: 12.55%
C: 8.0%
offering therapeutics
Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Published: 2021-12-09 (Crawled : 05:00) - prnewswire.com
RLMD | $3.91 1.03% 56K
|
Health Technology
|
| O: -3.85%
H: 12.55%
C: 8.0%
offering therapeutics
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M
|
AGBA | $2.355 88.4% 34M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.75 79.52% 1.5M
|
MTC | $2.28 46.15% 2.6M
|
Technology Services
OPRT | News | $3.14 39.56% 7.6M
|
Finance
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.865 33.21% 2.4M
|
n/a
PALI | $6.37 29.21% 21M
|
Manufacturing
LOCL | $3.33 27.59% 43K
|
Your saved searches
Save your searches and get alerts when important news are released.